Loading stock data…
Organon & Co (OGN)
$13.55+0.05 (+0.37%)
After Hours$13.55+0.00 (+0.00%)· Last close Jun 29
Organon & Co.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Organon & Co. in the Healthcare sector is trading at $13.55 with a market capitalization of $3.5B. Wall Street consensus targets $11.25 (4 analysts), implying a -17.0% move over the next 12 months. The stock is currently near its 52-week high of $13.55, remaining 47.8% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -17.0% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.46B↓ | $1.51B↓ | $1.60B↑ | $1.59B↑ | $1.51B |
| Gross Profit | $783.00M↑ | $741.00M↓ | $857.00M↓ | $874.00M↑ | $841.00M |
| Operating Income | $266.00M↑ | $217.00M↓ | $358.00M↑ | $326.00M↑ | $325.00M |
| Net Income | $146.00M↑ | -$205.00M↓ | $160.00M↑ | $145.00M↑ | $87.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internatio...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.53B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.44%
ROE
Elite ROE. Management converts capital into profit efficiently.
27.24%
Volume
Today's trading volume
1.07M
Recent News
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
It has been a banner year for biotech buyouts, and these are two of the prime targets.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is TOFIDENCE’s Expanded CRS and COVID Label Altering The Investment Case For Organon (OGN)?
Earlier in June 2026, Organon reported that the FDA approved a supplemental Biologics License Application for TOFIDENCE, expanding this tocilizumab biosimilar’s US label to cover CAR T cell-induced severe or life-threatening cytokine release syndrome and certain hospitalized COVID-19 patients, in addition to its existing autoimmune indications. This approval broadens TOFIDENCE’s eligible patient pool in critical-care and oncology-supportive settings, reinforcing Organon’s push to grow its US...
Organon (OGN) Stock After New TOFIDENCE Approval A Fresh Look At Valuation And Recovery Potential
What the TOFIDENCE approval means for Organon stock The latest catalyst for Organon (OGN) is the FDA approval of a supplemental Biologics License Application for TOFIDENCE, which broadens its use to severe cytokine release syndrome and certain hospitalized COVID-19 patients. This approval widens TOFIDENCE's potential patient pool in critical care and oncology related settings and reinforces Organon's focus on building out its biosimilar portfolio for high medical need areas. See our latest...
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19
OGN's TOFIDENCE gains FDA approval for life-threatening CRS and certain hospitalized COVID-19 patients, broadening its critical-care role.